Back to news

Quest Diagnostics Slides as Investors Weigh Medicare Lab Payment Cut Risk

Investivoq PriceTracker

Quest Diagnostics (DGX) is down 12.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be investor concern over proposed and pending Medicare laboratory reimbursement cuts that could pressure Quest Diagnostics’ revenue and margins beginning in 2027. The size of the drop suggests the market may also be pricing in broader worries about how much those payment changes could affect earnings beyond a single quarter.

Details:

  • Federal regulators recently outlined preliminary 2027 clinical laboratory payment rates that could reduce reimbursement for some tests by as much as 15%, creating a clear overhang for large independent lab operators.
  • Quest has publicly highlighted the risk of future Medicare lab payment reductions, and the company has been active in warning that additional cuts could affect access, volumes, and industry economics.
  • Company materials and recent filings show reimbursement policy remains an important business risk, especially because payment changes can directly affect profitability in routine diagnostic testing.
  • This could also be because investors are reassessing Quest’s 2027 earnings power ahead of its next quarterly report and looking for more detail on how management expects to offset any reimbursement pressure.

    • Sources:

    Quest Diagnostics, SEC, Investing.com

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $DGX Insider Trading Activity

    DGX Insider Trades

    $DGX insiders have traded $DGX stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

    Here’s a breakdown of recent trading of $DGX stock by insiders over the last 6 months:

    • MICHAEL E PREVOZNIK (SVP & General Counsel) has made 0 purchases and 3 sales selling 22,677 shares for an estimated $5,513,082.
    • J. E. DAVIS (CEO and President) has made 0 purchases and 2 sales selling 20,000 shares for an estimated $4,368,600.
    • KARTHIK KUPPUSAMY (SVP, Clinical Solutions) sold 8,147 shares for an estimated $1,629,400
    • MARK E DELANEY (SVP & Chief Commercial Officer) sold 1,600 shares for an estimated $376,288

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive DGX Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $DGX Hedge Fund Activity

    We have seen 521 institutional investors add shares of $DGX stock to their portfolio, and 432 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • JPMORGAN CHASE & CO added 3,520,438 shares (+inf%) to their portfolio in Q2 2026, for an estimated $746,156,834
    • PRICE T ROWE ASSOCIATES INC /MD/ removed 853,001 shares (-13.5%) from their portfolio in Q2 2026, for an estimated $180,793,561
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 773,711 shares (+inf%) to their portfolio in Q2 2026, for an estimated $163,988,046
    • BOSTON PARTNERS added 732,241 shares (+18.3%) to their portfolio in Q2 2026, for an estimated $155,198,479
    • EDGEPOINT INVESTMENT GROUP INC. added 586,496 shares (+35.3%) to their portfolio in Q2 2026, for an estimated $124,307,827
    • VICTORY CAPITAL MANAGEMENT INC removed 575,866 shares (-27.1%) from their portfolio in Q2 2026, for an estimated $122,054,798
    • FMR LLC added 456,517 shares (+48.5%) to their portfolio in Q2 2026, for an estimated $96,758,778

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $DGX Government Contracts

    We have seen $136,597,329 of award payments to $DGX over the last year.

    Here are some of the awards which we have have seen pay out the most over the last year:

    • FY27 TASK ORDER - 10/1/2026 - 6/30/2027: $7,162,140
    • PRIMARY REFERENCE LABORATORY TESTING / COURIER SERVICES / PHLEBOTOMY: $3,174,300
    • VISN 12 MULTI-SITE REFERENCE LABORATORY TESTING SERVICES FY27 TO: $3,110,000
    • REFERENCE LAB TESTS: $2,748,684

    To track government contracts to publicy traded companies, check out Investivoq's government contracts dashboard. You can access data on government contracts through the Investivoq API government contracts endpoint.

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.